Icosavax has launched out of University of Washington with $51m in series A funding to move a vaccine for respiratory syncytial virus into a phase 1b trial.
Icosavax, a US-based vaccine developer spun out of University of Washington (UW), made its public debut yesterday with $51m of series A funding led by venture capital firm Qiming Venture Partners USA.
Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, also contributed to the round, as did private equity firm Adams Street Partners, venture capital firm NanoDimension and undisclosed existing investors.
Founded in 2018, Icosavax is developing vaccines for infectious diseases using molecules known as virus-like…
